Precigen (PGEN) closed at $4.72 on November 11, 2026, up 4.4% from the previous close, on volume of 4,285,673 shares (30-day average 6,799,936).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 14, 2026 | Calendar Call Spread | 16-Oct-26 : 15-Jan-27 5.5 C | 608 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
ACCESS Newswire (Tue, 10-Nov 6:30 AM ET)
PRNewswire (Wed, 4-Nov 4:05 PM ET)
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
PRNewswire (Wed, 28-Oct 4:06 PM ET)
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
PRNewswire (Mon, 21-Sep 7:00 AM ET)
ACCESS Newswire (Tue, 25-Aug 7:00 AM ET)
PAPZIMEOS Drives Precigen to Profitability as Revenue More Than Doubles: What the Numbers Reveal
Market Chameleon (Wed, 5-Aug 7:11 AM ET)
Market Chameleon (Fri, 12-Jun 6:33 AM ET)
Market Chameleon (Thu, 14-May 6:16 AM ET)
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Precigen trades on the NASDAQ stock market under the symbol PGEN.
As of November 12, 2026, PGEN stock price declined to $4.69 with 1,931,008 million shares trading.
PGEN has a beta of 1.69, meaning it tends to be more sensitive to market movements. PGEN has a correlation of 0.05 to the broad based SPY ETF.
PGEN has a market cap of $1.68 billion. This is considered a Small Cap stock.
Last quarter Precigen reported $74 million in Revenue and $.08 earnings per share. This beat revenue expectation by $2 million and met earnings estimates .
In the last 3 years, PGEN traded as high as $8.98 and as low as $.65.
The top ETF exchange traded funds that PGEN belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.
PGEN has outperformed the market in the last year with a return of +18.4%, while the SPY ETF gained +12.3%. However, in the most recent history, PGEN shares have underperformed the stock market with its stock returning -31.6% in the last 3 month period and -22.9% for the last 2 week period, while SPY has returned -1.2% and -1.7%, respectively.
PGEN support price is $4.48 and resistance is $4.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PGEN shares will trade within this expected range on the day.
